8-K: Aquestive Reports Q3 2025 Results, Anaphylm Nears FDA Decision

Aquestive Therapeutics announced third quarter 2025 financial results, highlighted by Anaphylm's progress towards a January 2026 FDA decision and a strengthened balance sheet.

Summary

• Reported Q3 2025 financial results and provided a strategic business update.
• Anaphylm's New Drug Application (NDA) is on track for a January 31, 2026 PDUFA goal date, with the FDA confirming no Advisory Committee meeting is required.
• Preparations are underway for a potential U.S. launch of Anaphylm in Q1 2026, if approved, alongside advancing regulatory discussions in Canada and the EU.
• Two new patents for Anaphylm were issued in October 2025, extending protection into 2037.
• AQST-108, a topical epinephrine gel for alopecia areata, is on track for an Investigational New Drug (IND) application submission in Q4 2025, with a clinical study expected in 1H 2026.
• The balance sheet was strengthened by an $85 million equity raise in August 2025 and a strategic financing commitment of $75 million from RTW Investments, LP, contingent on Anaphylm's FDA approval and debt refinancing.
• Total revenues for Q3 2025 were $12.8 million, a decrease from $13.5 million in Q3 2024 (which included a one-time deferred revenue recognition). Excluding this, revenues increased by $0.5 million (4%) year-over-year.
• Net loss for Q3 2025 was $15.4 million, or $0.14 per share, compared to a net loss of $11.5 million, or $0.13 per share, in Q3 2024.
• Non-GAAP adjusted EBITDA loss was $8.6 million in Q3 2025, compared to $6.6 million in Q3 2024.
• Cash and cash equivalents stood at $129.1 million as of September 30, 2025, with a projected cash runway into 2027.
• Full-year 2025 guidance includes total revenue of $44 to $50 million and a non-GAAP adjusted EBITDA loss of $47 to $51 million.

Sentiment

Score: 6

Explanation: The company made substantial regulatory and commercial progress for Anaphylm, including a clear PDUFA date and no Advisory Committee, and significantly strengthened its financial position through recent capital raises. However, this progress is accompanied by increased net losses and higher operating expenses, reflecting pre-commercialization investments. The future outlook hinges heavily on Anaphylm's FDA approval.

Positives

• FDA confirmed no Advisory Committee meeting for Anaphylm, streamlining the regulatory path.
• Anaphylm's NDA remains on track for its January 31, 2026 PDUFA goal date.
• Successful clinical site inspections for Anaphylm's adult pivotal studies with no major findings.
• Broadened patent estate for Anaphylm with two new patents extending protection into 2037.
• Strengthened balance sheet with an $85 million equity raise and a $75 million strategic financing commitment.
• Research and development expenses decreased to $4.5 million in Q3 2025 from $5.3 million in Q3 2024.
• Manufacture and supply revenue increased to $11.5 million in Q3 2025 from $10.7 million in Q3 2024, driven by Sympazan and Suboxone.
• Projected cash runway into 2027.
• Advancing global expansion strategy for Anaphylm with regulatory engagement in Canada and preparatory efforts in the EU.
• AQST-108 for alopecia areata is on track for IND submission in Q4 2025 and clinical study in 1H 2026, addressing an unmet need.

Negatives

• Net loss increased to $15.4 million in Q3 2025 from $11.5 million in Q3 2024.
• Selling, general and administrative expenses increased significantly to $15.3 million in Q3 2025 from $12.1 million in Q3 2024, primarily due to higher commercial spending, legal fees, and regulatory expenses for Anaphylm.
• Non-GAAP adjusted EBITDA loss increased to $8.6 million in Q3 2025 from $6.6 million in Q3 2024.
• Total revenues decreased to $12.8 million in Q3 2025 from $13.5 million in Q3 2024, when including a one-time deferred revenue recognition in the prior year.
• Libervant remains tentatively approved until January 11, 2027, due to existing orphan drug exclusivity of a competitor.

Risks

• Delays or changes to the timing, cost, and success of product development activities and clinical trials, including for Anaphylm, AQST-108, and other product candidates.
• Delays in the regulatory approval process through the FDA for product candidates, or failure to receive FDA approval at all.
• Risk of FDA inspections of manufacturing and clinical study sites for any product candidates, including Anaphylm.
• Risk of government shutdown impacting the FDA's ability to act on product candidate approvals.
• Inability to generate sufficient clinical data for approval of product candidates, including with respect to pharmacokinetic and pharmacodynamic (PK/PD) comparability submission for FDA approval of Anaphylm.
• Inability to address the FDA's comments on the NDA, including the risk that the FDA may require additional clinical studies for approval of Anaphylm.
• Success of any competing products, including generics.
• Risks and uncertainties inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations).
• Risk of development of a sales and marketing capability for commercialization of product candidates, including Anaphylm, Libervant and AQST-108.
• Potential impact on the value of the company of the sale or outlicensing of products and product candidates, including Libervant and Anaphylm and other product candidates.
• Risk of insufficient capital and cash resources, including sufficient access to available debt and equity financing, and revenues from operations, to satisfy all short-term and longer-term liquidity and cash requirements and other cash needs, including to commence principal payments on 13.5% Senior Secured Notes in 2026, and to fund future clinical development and commercial activities for product candidates.
• Impact of obligations under the Purchase Agreement and the Royalty Rights Agreement with third parties, each of which requires payments of a portion of revenues, on the ability to contribute to the funding of operations and the payment of principal and interest on debt.
• Risk of obligations under such Purchase Agreement and Royalty Rights Agreement impacting the ability to refinance 13.5% Senior Secured Notes.
• Manufacturing capabilities may be insufficient to support demand of product candidates in the U.S. and abroad, if such product candidates should be approved by the FDA and other regulatory authorities, and licensed products in the U.S. and abroad.
• Risk of eroding market share for Suboxone as a sunsetting product, which accounts for a substantial part of current operating revenue.
• Risk of default of debt instruments.
• Risks related to the outsourcing of certain sales, marketing and other operational and staff functions to third parties.
• Risk of the rate and degree of market acceptance in the U.S. and abroad of Libervant, Anaphylm, AQST-108 and other product candidates, should these product candidates be approved by the FDA and other regulatory authorities, and for licensed products in the U.S. and abroad.
• Risk associated with the size and growth of product markets.
• Risk associated with compliance with all FDA and other governmental and customer requirements for manufacturing facilities.
• Risks associated with intellectual property rights and infringement claims relating to products.
• Risk that patent applications for product candidates, including for Anaphylm and AQST-108, will not be timely issued, or issued at all, by the U.S. Patent and Trademark Office or, if issued, will be sufficient to provide long-term commercial success of these product candidates.
• Risk of unexpected patent developments.
• Risk of legislation and regulatory actions and changes in laws or regulations affecting the business including relating to products and product candidates and product pricing, reimbursement or access therefor.
• Risk of loss of significant customers.
• Risks related to claims and legal proceedings against the company including patent infringement, securities, business torts, investigative, product safety or efficacy and antitrust litigation matters.
• Risk of product recalls and withdrawals.
• Risks related to any disruptions in information technology networks and systems, including the impact of cybersecurity attacks.
• Risk of increased cybersecurity attacks and data accessibility disruptions due to remote working arrangements.
• Risk of adverse developments affecting the financial services industry.
• Risks related to inflation and changing interest rates.
• Risks related to the impact of other pandemic diseases on the business.
• Risks and uncertainties related to general economic, political (including the Ukraine and Israel wars and other acts of war and terrorism), business, industry, regulatory, financial and market conditions and other unusual items.
• Risks related to uncertainty about presidential administration initiatives and their impact on the business, including imposition of government tariffs and other trade restrictions.

Future Outlook

The company anticipates a potential U.S. launch of Anaphylm in the first quarter of 2026, pending FDA approval by the scheduled January 31, 2026 PDUFA goal date. It plans to submit an Investigational New Drug application for AQST-108 in Q4 2025, with a clinical study commencing in the first half of 2026. Full-year 2025 total revenue is projected to be between $44 million and $50 million, with a non-GAAP adjusted EBITDA loss of $47 million to $51 million. The company also projects a cash runway into 2027.

Management Comments

• "The third quarter was another period of strong execution for Aquestive as we move closer to the launch of Anaphylm, if approved by the FDA."
• "The FDA’s decision not to convene an Advisory Committee further advances our regulatory path, and our NDA remains on track for the scheduled January 31, 2026 PDUFA goal date."
• "We are fully engaged in U.S. launch preparations, continuing to build commercial readiness across distribution, medical affairs, and marketing channels, while also advancing regulatory discussions in Canada and the EU."
• "Following our recently completed equity financing and strategic funding commitments, we believe we are well positioned to deliver on our mission to make epinephrine emergency treatment more accessible, portable, and patient-friendly."
• "Finally, we remain committed to developing additional products from our AdrenaVerse epinephrine prodrug platform."

Industry Context

Aquestive's Anaphylm, if approved, could disrupt the anaphylaxis treatment market by offering the first and only oral, needle-free epinephrine option, potentially improving patient compliance and accessibility compared to existing injectable auto-injectors. This aligns with a broader trend towards less invasive drug delivery methods. For alopecia areata, AQST-108 aims to address a significant unmet need by providing a targeted, non-systemic topical treatment, contrasting with current systemic and costly Janus kinase (JAK) inhibitors that carry black box warnings, positioning it to capture meaningful market share in a growing segment.

Comparison to Industry Standards

• Anaphylm aims to be the first and only oral medication for severe allergic reactions, offering a needle-free, portable, and easy-to-administer formulation, which would be a significant differentiator from existing epinephrine auto-injectors (e.g., EpiPen, Auvi-Q).
• AQST-108 for alopecia areata is designed as a topical, locally acting epinephrine gel, contrasting with existing systemic Janus kinase (JAK) inhibitors (e.g., Olumiant, Litfulo) which are costly and carry black box warnings, potentially offering a safer and more targeted alternative.

Stakeholder Impact

• Shareholders: Potential for significant value creation if Anaphylm is approved and successfully launched, but also risk from increased losses and reliance on future approvals. The recent equity raise diluted existing shareholders.
• Patients (Anaphylaxis): Potential for a novel, needle-free, and more accessible treatment option (Anaphylm) if approved, improving compliance and outcomes.
• Patients (Alopecia Areata): Potential for a targeted, non-systemic treatment option (AQST-108) without the black box warnings of existing systemic therapies.
• Employees: Continued investment in commercial and medical infrastructure suggests potential for growth and new roles, particularly for Anaphylm launch.
• Creditors: The company's ability to commence principal payments on Senior Secured Notes in 2026 and refinance debt is a key consideration, with the strategic financing contingent on Anaphylm approval.

Next Steps

• Continue U.S. launch preparations for Anaphylm, if approved by the FDA.
• Advance regulatory discussions for Anaphylm in Canada and the EU.
• Submit an Investigational New Drug (IND) application for AQST-108 to the FDA in Q4 2025.
• Initiate a clinical study for AQST-108 for Alopecia Areata in 1H 2026.
• Host an investor conference call on November 6, 2025, at 8:00 a.m. ET.
• Await FDA action on Anaphylm's NDA by the January 31, 2026 PDUFA goal date.
• Await potential licensee-led U.K. regulatory approval for Libervant in Q1 2026.
• Commence principal payments on 13.5% Senior Secured Notes in 2026.

Key Dates

Recommendation

While Aquestive has made significant progress with Anaphylm's regulatory path and strengthened its balance sheet, the company continues to report increased net losses and higher operating expenses as it invests heavily in pre-commercialization activities. The future success is highly dependent on the FDA approval of Anaphylm by January 2026 and its subsequent commercial launch. Given the binary nature of FDA approval and the substantial investment required for launch, a 'hold' recommendation is appropriate. Investors should monitor the PDUFA decision closely and assess the initial launch trajectory before making further investment decisions. The long-term potential is significant if Anaphylm succeeds, but near-term risks and costs are considerable.

Keywords

Aquestive Therapeutics, AQST, Anaphylm, dibutepinephrine, Sublingual Film, anaphylaxis, FDA approval, PDUFA, AQST-108, alopecia areata, epinephrine topical gel, Libervant, diazepam buccal film, Q3 2025 earnings, pharmaceuticals, drug development, biotechnology, PharmFilm, AdrenaVerse, financial results, NDA, IND, patent protection, capital raise, cash runway